Viracta Therapeutics Inc (VIRX)
0.8102
-0.03
(-3.55%)
USD |
NASDAQ |
May 03, 16:00
0.822
+0.01
(+1.46%)
After-Hours: 20:00
Viracta Therapeutics Cash from Investing (TTM): 15.00M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 15.00M |
September 30, 2023 | 5.525M |
June 30, 2023 | -55.63M |
March 31, 2023 | -61.22M |
December 31, 2022 | -53.87M |
September 30, 2022 | -53.68M |
June 30, 2022 | -5.853M |
Date | Value |
---|---|
March 31, 2022 | -4.252M |
December 31, 2021 | 12.89M |
September 30, 2021 | 12.91M |
June 30, 2021 | 17.13M |
March 31, 2021 | 17.09M |
December 31, 2020 | -0.055M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-61.22M
Minimum
Mar 2023
17.13M
Maximum
Jun 2021
-11.85M
Average
-0.055M
Median
Dec 2020
Cash from Investing (TTM) Benchmarks
XOMA Corp | -0.711M |
Marinus Pharmaceuticals Inc | -28.60M |
Cartesian Therapeutics Inc | 34.61M |
Adial Pharmaceuticals Inc | -- |
NovaBay Pharmaceuticals Inc | -0.019M |